Skip to main content
Premium Trial:

Request an Annual Quote

NCI's CPTC Issues New Call for Antibody Targets

Premium

The National Cancer Institute's Clinical Proteomic Technologies for Cancer Initiative this week issued a request for targets for monoclonal antibody production and characterization as part of its Antibody Characterization Program.

The organization will accept submissions through July 9 and will review them "based on their justification and contribution to existing NCI-funded projects," the request said. It added that "priority will be given to projects applying the antibodies to proteomics research."

The Antibody Characterization Program generates monoclonal antibodies to proteins associated with human cancer for use in the CPTC initiative. Three antibodies are generated for each protein target and characterized using assays including isotype, SDS-PAGE, Western blot, ELISA, immunohistochemistry, immuno mass spectroscopy, and surface plasmon resonance.

Antibodies and hybridoma cells are made available to researchers through the Developmental Studies Hybridoma Bank at the University of Iowa and other third-party resources.

Successful applicants will be notified on or before Aug. 30. All materials – i.e. proteins or peptides – to be used for antibody development must be ready and available at the time of the request submission.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.